Clinical epidemiology of epithelial ovarian cancer in the UK

International Journal of Women's Health

Volumn 6, Issue 1, 2014, Pages 537-545

  Doufekas, Konstantinos ^a   Olaitan, Adeola ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Cancer; Epidemiology; Incidence; Ovarian; Survival; UK

Indexed keywords

ANTINEOPLASTIC AGENT; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL HYSTERECTOMY; AGE; BREAST FEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; ENDOMETRIOSIS; FAMILY HISTORY; GEOGRAPHY; HORMONE SUBSTITUTION; HUMAN; INFERTILITY; MENSTRUATION; OMENTECTOMY; OVARY CARCINOMA; PARITY; REVIEW; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; UNITED KINGDOM;

EID: 84901417010     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S40894     Document Type: Review

References (70)

1. Berrino F, De Angelis R, Sant M, et al; EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773-783.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No 5, Version 2.0. Lyon: IARC Press; 2004.
3. Ovarian cancer statistics [webpage on the Internet]. Oxford: Cancer Research UK; 2013 [updated Jan 2013]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/. Accessed January 10, 2014.
4. Targeted Therapies for the Management of Ovarian Cancer (Scientific Impact Paper No 12) [webpage on the Internet]. London: Royal College of Obstetricians and Gynaecologists; 2013. Available from: http://www.rcog.org.uk/womens-health/clinical-guidance/targeted-therapies-managment-ovarian-cancer. Accessed January 10, 2014.
5. Overview of Ovarian Cancer in England: Incidence, Mortality and Survival (Nov 2012) [webpage on the Internet]. London: National Cancer Intelligence Network. Available from: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/gynaecological_cancer/gynaecological_cancer_hub/resources/ovarian_cancer. Accessed January 10, 2014.
6. De Angelis R, Sant M, Coleman MP, et al; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):23-34.
7. Coleman MP, Forman D, Bryant H, et al; ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127-138.
8. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer. 2001;11(6):423-429.
9. Grosios K, Gahan PB, Burbidge J. Overview of health care in the UK. EPMA J. 2010;1(4):529-534.
10. Equity and Excellence: Liberating the NHS. Department of Health publications; 2010. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213823/dh_117794.pdf. Accessed January 10, 2014.
11. The NHS in England [webpage on the Internet]. London: National Health Service; 2013. Available from: http://www.nhs.uk/NHSEngland/thenhs/about/Pages/overview.aspx. Accessed January 10, 2014.
12. Morris E, Haward RA, Gilthorpe MS, Craigs C, Forman D. The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire's colorectal cancer patients. Br J Cancer. 2006;95(8):979-985.
13. Guidance on Commissioning Cancer Services: Improving Outcomes in Gynaecological Cancers-The Mannual. Department of Health; 1999. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4005385. Accessed January 10, 2014.
14. The NHS Cancer Plan: a Plan for Investment, a Plan for Reform. London: Department of Health; 2000. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyandGuidance/DH_4009609. Accessed January 10, 2014.
15. Characteristics of an Effective Multidisciplinary Team (MDT) [webpage on the Internet]. London: National Cancer Intelligence Network; 2010. Available from: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/multidisciplinary_teams/mdt_development. Accessed January 10, 2014.
16. Kitchener HC. Gynaecological cancer services: time for change. BJOG. 1997;104(2):123-126.
17. Olaitan A, McCormack M. Centralisation of services for the management of ovarian cancer: arguments for. BJOG. 2007;114(10):1188-1190.
18. Crawford SM, Brunskill PJ. Centralisation of services for the management of ovarian cancer: arguments against. BJOG. 2007;114(10):1183-1185; discussion 1186-1187.
19. Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancer. Cochrane Database Syst Rev. 2012;3:CD007945.
20. United Kingdom Association of Cancer Registries Home Page [homepage on the Internet]. United Kingdom Association of Cancer Registries; 2013. Available from: http://www.ukacr.org/. Accessed January 10, 2014.
21. National Institute for Health Care and Excellence. Ovarian Cancer: the Recognition and Initial Management of Ovarian Cancer. Full Guideline (Apr 2011). London: National Institute for Health Care and Excellence; 2012. Available from: http://www.nice.org.uk/nicemedia/live/13464/54266/54266.pdf. Accessed January 10, 2014.
22. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61(2):152-163.
23. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1-5.
24. Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl. 1995;23:200-207.
25. Kirwan J. Ovarian cancer standards of care. In: Acheson N, Luesly D, editors. Gynaecological Oncology for the MRCOG and Beyond. London: RCOG Press; 2010:115-143.
26. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2):74-108.
27. Ovarian cancer risks and causes [webpage on the Internet]. London: Cancer Research UK; 2013 [updated November 29, 2013]. Available from: http://www.cancerresearchuk.org/cancer-help/type/ovarian-cancer/about/ovarian-cancer-risks-and-causes. Accessed January 10, 2014.
28. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343(8899):692-695.
29. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Williston Park). 1998;12(3):399-406.
30. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265-271.
31. Rosenthal A, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31(1):49-57.
32. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 1994;140(7): 585-597.
33. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250-1254.
34. Whittemore A, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1212-1220.
35. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284-290.
36. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet. 1995;346(8981):995-1000.
37. Vlahos NF, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. Ann N Y Acad Sci. 2010;1205:214-219.
38. Zreik TG, Ayoub CM, Hannoun A, Karam CJ, Munkarah AR. Fertility drugs and risk of ovarian cancer: dispelling the myth. Curr Opin Obstet Gynecol. 2008;20(3):313-319.
39. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011;105(9): 1436-1442.
40. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8): 894-901.
41. Collaborative Group on Epidemiological Studies of ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-314.
42. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer. 1995;71(6):1340-1342.
43. McLaughlin JR, Risch HA, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26-34.
44. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol. 1998;92(3):472-479.
45. Beral V; Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703-1710.
46. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733-740.
47. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand. 2004;83(4):395-400.
48. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75(6):1023-1028.
49. Melin AS, Lundholm C, Malki N, Swahn ML, Sparèn P, Berqqvist A. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2013;92(5):546-554.
50. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast cancer patients with a family history of breast or ovarian cancer: a population based cohort study. Lancet. 2002;360(9337):891-894.
51. Ovarian cancer risk factors [webpage on the Internet]. Cancer Research UK [Updated November 2013]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/riskfactors/. Accessed March 31, 2014.
52. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long term risk. J Natl Cancer Inst. 2007;99(21):1634-1643.
53. Bates C. More women putting off starting a family as average age of having a baby climbs to 29 [webpage on the Internet]. London: Mail Online; October 20, 2011. Available from: http://www.dailymail.co.uk/health/article-2051374/Average-age-women-having-baby-climbs-29-start-family-later.html. Accessed January 10, 2014.
54. Olaitan A, Mocroft A, Jacobs I. Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG. 2000;107(9):1094-1096.
55. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-781.
56. Ovarian cancer incidence statistics [webpage on the Internet]. London: Cancer Research UK; 2011 [updated November 4, 2011]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/uk-ovarian-cancer-incidence-statistics. Accessed January 10, 2014.
57. Tate AR, Nicholson A, Cassell JA. Are GPs under investigating older patients presenting with symptoms of ovarian cancer? Observational Study using General Practice Research Database. Br J Cancer. 2010;102(6):947-951.
58. Walters S, Quaresma M, Coleman MP, Gordon E, Forman D, Rachet B. Geographical variation in cancer survival in England, 1991-2006: an analysis by Cancer Network. J Epidemiol Community Health. 2011;65(11):1044-1052.
59. Oberaigner W, Minicozzi P, Bielska-Lasota M, et al; Eurocare Working Group. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4): 441-453.
60. Differences in treatment for advanced ovarian cancer could explain why UK survival lags behind other countries [webpage on the Internet]. London: Cancer Research UK; 2012 [updated October 3, 2012]. Available from: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/differences-in-treatment-for-advanced-ovarian-cancer-could-explain-why-uk-survival-lags-behind-other. Accessed January 10, 2014.
61. Short Term Ovarian Cancer Mortality [webpage on the Internet]. London: National Cancer Intelligence Network. Available from: http://www.ncin.org.uk/publications/data_briefings/short_term_ovarian_cancer_mortality. Accessed January 10, 2014.
62. Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197(2): 198-205.
63. Chang SJ, Bristow RE, Ryu HS. Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J Gynecol Oncol. 2013;24(1):29-36.
64. Olaitan A. NICE on ovarian cancer: Recommendations for detection in primary care are flawed. BMJ. 2011;342:d3022.
65. Vergote I, Tropé CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953.
66. Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. In: Proceedings of the 18th International Meeting of the European Society of Gynaecological Oncology; October 19-22, 2013; Liverpool, UK. Abstract 5500.
67. Naik R, Edmondson RJ, Galaal K, Hatem MH, Godfrey KA. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG. 2008;115(13):1713-1714; author reply 1714.
68. Pomel C, Barton DP, McNeish I, Shepherd J. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG. 2008;115(7):808-810.
69. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced stage ovarian cancer. Obstet Gynecol. 2006;107(1):77-85.
70. Butler J, Gildea C, Meechan D, Nordin A. Ovarian Cancer Surgery by Specialists in Specialist Centres. Proceedings of the 2011 UKacr/NCIN conference: Liberating Information, Improving Outcomes; 2011 June 15-17; London, UK.